• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • COVID-19
  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

5 Ways SmartTrials is Advancing Precision Medicine Through Genomics

by Erica Garvin 06/04/2018 Leave a Comment

 5 Ways SmartTrials is Advancing Precision Medicine Through Genomics

Foundation Medicine’s Dr. Gaurav Singal shares how his company’s platform is changing the game in clinical trials and bolstering precision medicine through genomics.

The evolution may be slow going, but it looks like precision medicine is destined to disrupt many aspects of healthcare, and it’s already demonstrating that transformative power in clinical trials—where patient recruitment and retention have long plagued the process, according to Foundation Medicine’s Dr. Gaurav Singal.

“Current clinical trial design and patient identification and recruitment strategies are challenging, especially in a molecular-driven time,” said Singal, vice president of data strategy and product development at the Cambridge, MA-based genomic analysis and diagnostics provider. “Often, patients are narrowly defined and widely distributed geographically. As we worked with a multitude of pharma partners, we began to see this challenge reoccurring; partners were developing medicines for rarer targets and were having significant trouble getting those medicines to patients with those rare targets.”

Satisfying that need to match those more specialized patients and treatments more effectively was the inspiration behind FMI’s Smart Trials technology platform. The company is now using the platform in to rapidly match the right patients to precision trials through genomic testing and the identification of unique tumor biomarkers.

“We have a full suite of comprehensive genomic profiling assays to identify the molecular alterations in a patient’s cancer and match them with relevant, targeted therapies, immunotherapies, and clinical trials. Our molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers, and drug developers to help advance the science of molecular medicine in cancer,” said Singal.

5 Ways SmartTrials is Advancing Precision Medicine Through Genomics

There is no doubt there is reciprocity between the advancements of clinical trials and precision medicine. Precision-focused tools like SmartTrials are uncovering the connections between patients and personalized treatments—and the data from those trials will ultimately be used to further advanced those precision-based tools, care-access techniques, and treatments. It’s with that aim in mind, SmartTrials is already demonstrating its power in several ways within several clinical trials.

Here are five ways this innovative platform is advancing precision medicine research and development and transforming the clinical trial process along the way:

1. Boosting Enrollment: SmartTrials is helping to accelerate patient enrollment in TAPUR, a biomarker-driven clinical trial. Foundation Medicine is leveraging patients’ genomic profiling results to connect them to TAPUR trial sights automatically. Use of SmartTrials in TAPUR has already led to a significant increase in patient enrollment, reporting more than 60 patients within a few months of implementing the technology at one site.

2. Advancing Access and Eligibility: SmartTrials is also supporting enrollment for The National Cancer Institute’s (NCI) “MATCH” precision medicine trial. SmartTrials will automatically notify physicians when their patients’ genomic profiling results make them eligible for a treatment arm within the trial.

3. Improving Drug Development: Research results recently highlighted how SmartTrials helped match non-small cell lung cancer patients to a Phase II trial based on their biomarker. Researchers concluded that these “innovative partnerships, combined with computational matching infrastructure, could improve drug development and therapeutic access.”

4. Demonstrating the Benefit of Genomic Matching: Loxo’s Larotrectinib could be available to patients with the TRK biomarker as early as next year and Merck’s Keytruda was FDA approved recently for patients with the MSI biomarker. Both therapies are evidence that more patients could benefit from joining clinical trials based on their biomarker.

5. Saving Lives: FMI has witnessed firsthand the personal benefits of genomic matching. One example: a prostate cancer patient named David, who’s genomic testing results guided him to a clinical trial that wasn’t even studying prostate cancer at the time. However, because the therapy was targeted to his cancer’s specific makeup, David’s enrollment turned out to be a lifesaver. He is now in complete remission.

Perhaps the most compelling advancements are the ones that seem the most personal: “Stories like David’s support the benefits of precision medicine-based approaches for clinical research and treatment. As the field discovers therapeutic targets or biomarkers, more patients have the potential to receive lifesaving treatment,” Singal concluded.

Tagged With: Clinical Genomics, Clinical Trials, Foundation Medicine, genomics data, Precision Medicine, SmartTrials

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Most Popular

Survey: Clinician Burnout Is A Public Health Crisis Demanding Urgent Action

17 Execs Share How Health IT Can Address Clinician Burnout, Staffing, & Capacity

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Q/A: Dr. Johnson Talks Racial Disparities in Breast Cancer Care

Northwell Health Extends Contract with Allscripts Sunrise Platform Through 2027

Northwell to Deploy Epic Enterprise EHR Platform Across System

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Sanofi Cuts Price of Lantus Insulin by 78% & Caps Out of Pocket Costs at $35 for All Patients

Pfizer Acquires Seagen for $43B to Tackle Cancer

Pfizer Acquires Seagen for $43B to Tackle Cancer

5 Key Trends Driving Purchasing Decisions in Healthcare IT

5 Key Trends Driving Purchasing Decisions in Healthcare IT

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B

Dr. Arti Masturzo

Q/A: Dr. Masturzo Talks Addressing Food Insecurity with Patients

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Transcarent Acquires 98point6 AI-Powered Virtual Care Platform and Care Business

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Eli Lilly Cuts Insulin Prices by 70%, Caps Patient Costs at $35 Per Month

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2023 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2023. HIT Consultant Media. All Rights Reserved. Privacy Policy |